ARK Fintech Innovation ETF vs GSK plc — how do they compare? ARK Fintech Innovation ETF trades at $43, while GSK plc trades at $50.15 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while ARK Fintech Innovation ETF pays none, and GSK plc is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | GSK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $61.18 |
52-Week Low | $36.14 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →